NCT02259972View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113823 Powder in Bottle (PiB) and Tablet in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

June 30, 2010

Conditions
Healthy
Interventions
DRUG

BI 113823 solution

DRUG

BI 113823 tablet

DRUG

Placebo

OTHER

High fat, high calorie breakfast

only for dose group 5

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02259972 - Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113823 Powder in Bottle (PiB) and Tablet in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter